Positron taps affiliate for $2M credit line to fund PET-CT launch
What's the deal? Positron Corporation (OTC: POSC) has secured a line of credit of up to $2 million from George Ortiz, an existing affiliated investor. The agreement, dated 13 August 2026, gives the medical imaging company discretionary access to financing for working capital and product commercialisation.
The terms. Draws are capped at $500,000 per quarter, with a $50,000 minimum, and repaid amounts can be reborrowed. Interest is fixed at 12% per annum, with an interest-only period for the first year before principal payments begin. All advances mature on 13 August 2028.
What's the endgame? Positron plans to use the liquidity to fund working capital and the commercialisation of its new PET-CT platform, according to the filing. The company may prepay without penalty.
The cost. In exchange, Positron issued Ortiz warrants to buy 300,000 shares at $1.50 each, expiring 31 December 2030. The exercise price automatically reprices to $1.00 on a payment default, increasing potential dilution.
What could go wrong? The 12% fixed rate is above traditional lending costs, and the warrants carry dilution risk for existing shareholders. Negative covenants also require lender consent for major moves such as mergers or asset sales, which could limit Positron's strategic flexibility.
The signal. A small-cap firm turning to an affiliated investor for high-cost debt points to constrained capital access. For Positron, the facility provides runway to bring its PET-CT platform to market while adding interest and potential dilution costs.
Read more: MiniChart
Image credit: JOHN K THORNE
